STK11 and KEAP1 Mutations: Why They Matter in Lung Cancer
STK11 and KEAP1 are genes that, when mutated โ often alongside KRAS mutations โ are associated with weaker responses to standard immunotherapy combinations in non-small cell lung cancer, prompting a specific wave of research targeting this subgroup.
STK11 and KEAP1 mutations affect cellular pathways involved in metabolism and oxidative stress response, and tumors carrying these mutations, particularly in combination with KRAS mutations, have consistently shown weaker responses to typical checkpoint-inhibitor-based immunotherapy regimens in multiple studies.
This finding has prompted specific biomarker-guided trials, such as the TRITON study, testing whether adding a second immune-checkpoint-targeting antibody or other novel combination strategies can improve outcomes specifically for this genetically defined, harder-to-treat subgroup.
STK11 and KEAP1 co-mutation status is an example of how genomic testing has moved beyond identifying a single 'driver' mutation toward characterizing a fuller genomic profile that can meaningfully affect predicted treatment response.
Frequently Asked Questions
Does having an STK11 or KEAP1 mutation mean immunotherapy won't work at all?
It's associated with statistically weaker average response in study populations, not a guarantee of no benefit for any individual; discuss your specific test results with your oncologist.
Are STK11/KEAP1 mutations common in lung cancer?
They occur in a meaningful subset of NSCLC cases, often alongside KRAS mutations, and are increasingly tested for as part of comprehensive genomic profiling.